Loading
Life sciences · Observational Study
ClinicalTrials.gov · September 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Observational Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT04000061). This is a study registration, not published results. Lead sponsor: University Hospital, Basel, Switzerland. Recruitment status: RECRUITING. Study type: OBSERVATIONAL. Enrollment: 6000 participants (ESTIMATED). Conditions: Acute Heart Failure, Acute Coronary Syndrome. Interventions: OTHER: medical chart review; OTHER: data generated by direct IT export. Primary outcome measures: number of all-cause death , 1 to 8 years after hospitalization; number of HF hospitalizations , 1 to 8 years after hospitalization; number of cardiovascular death , 1 to 8 years after hospitalization; number of cardiovascular hospitalizations , 1 to 8 years after hospitalization. Brief summary: This retrospective cohort study is to identify triggers of heart failure (HF) development and drivers of HF progression as well as the underlying cardiac disease (phenotype) to identify patients at risk and predict the clinical course of the disease. Data of patients who were hospitalized during the years 2010-2023 with acute coronary syndrome (ACS) and/ or with acute heart failure (AHF) will be collected and analyzed. In a subgroup cohort efficacy and safety of digoxin in patients with acute heart failure triggered by tachyarrhythmia will be evaluated.